There is a very, very interesting article: “Cheap, safe drug kills most cancers” in this week’s New Scientist about a drug that could potentially work on all cancers. The same edition’s editorial is about how it might not come to fruition due to the drug been old and therefore not patentable as the pharmaceutical industry won’t make any money from it.
In a normal cell energy is produced in the mitochondria but in a cancer cell another process called glycolysis is used. This is common to all cancers. It was generally thought that cancer cells used glycolysis because the mitochondria was irreparably damaged but it turns out that it just shuts down because there is not enough oxygen. The problem with this is that the mitochondria controls apoptosis (or cell death — which is a normal part of a cell’s life cycle) so the cell becomes immortal and cancerous.
Now if a patient is treated with dichloroacetate (DCA) the mitochondria restarts and apoptosis starts working again and the cell is shut down in the normal manner thereby killing the cell. Well that’s the theory anyway!
This all sounds amazing stuff and it has been tested on human cancer cells outside the body and on rats that have been infected with human cancer cells and the results have been very good. There have been no human trials as of yet. And this is where it gets to the sad part. This drug has been around for years and therefore not patentable. What’s more there is no incentive for any of the pharmaceutical companies to develop this drug as they are not going to make any money from it. This I think is absolutely reprehensible and is a stunningly example of how neoclassical economics has once again let us all down (If you want a full analysis of why neoclassical economics is so utterly screwed I suggest the you read “Economia - New Economic Systems to Empower People and Support the Living World” by Geoff Davies. It is quite an amazing read). In a more just economic system there would be a mechanism that forces the pharmaceutical companies to at least contribute to the development of drugs that profit society but not the pharmaceutical industry. After all corporations were started to benefit society not the other way around.
Now I am not saying that this drug is going to work — I’m an engineer I am so not qualified to make that statement — but I am qualified to say that it should as least be trialled to see if it does work. As the New Scientist editorial says:
It is a safe bet that drug companies will be falling over themselves to find patentable compounds with a similar action to DCA.
It goes on to say:
It would be a scandal if a cheap alternative with such astonishing potential were not given a chance simply because it won’t turn a big enough profit
It would an absolute scandal.
Further reading:
Pharmaceutical Corporations and Medical Research